FLUARIX (trivalent influenza vaccine (split virion, inactivated)) - Influenza vaccine
Reason for request
Summary of opinion
Favourable opinion for reimbursement in the prophylaxis of influenza in adults and children from 6 months of age and in accordance with the current vaccination recommendations (HAS opinion of 8 July 2025).
Clinical Benefit
| Substantial |
The clinical benefit of FLUARIX (trivalent influenza vaccine (split virion, inactivated)) is substantial in the prophylaxis of influenza in adults and children from 6 months of age in accordance with the current HAS vaccination recommendations dating from 8 July 2025. |
Clinical Added Value
| no clinical added value |
The change from tetravalent to trivalent is not of a nature to modify the clinical added value. The Committee considers that FLUARIX (trivalent influenza vaccine (split virion, inactivated)) provides no clinical added value (CAV V), in adults and children from 6 months of age for whom vaccination is recommended, compared to the other vaccines recommended in the prevention of seasonal influenza. |
